ReviewJournal of cancer research and clinical oncology2016
Clinical challenges with calcitonin-negative medullary thyroid carcinoma.
Review in Journal of cancer research and clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- New Neuroendocrine Markers PITX2, PHOX2B, and HAND2 Do Not Offer Diagnostic Utility in Fine-needle Aspiration Biopsies of Primary and Secondary Medullary Thyroid Carcinomas: A Retrospective Multi-institutional Study.Journal of clinical and translational pathology · 2026Article
- Calcitonin-negative medullary thyroid carcinoma combined with multifocal papillary thyroid carcinoma: a case report and literature review.BMC endocrine disorders · 2026Review
- Diagnostic challenges in calcitonin negative medullary thyroid carcinoma: a systematic review of 101 cases.Gland surgery · 2024Review
- Management of medullary thyroid cancer based on variation of carcinoembryonic antigen and calcitonin.Frontiers in endocrinology · 2024Review
- Article
- A Rare Case of Negative Serum Calcitonin in Metastatic Medullary Thyroid Carcinoma: Diagnosis, Treatment, and Follow-Up Strategy.The American journal of case reports · 2022Article
- Clinical challenges with calcitonin-negative medullary thyroid carcinoma: three case reports and a review of the literature.Annals of the Royal College of Surgeons of England · 2022Review
- "Triple-negative" non-secretory medullary thyroid cancer: uncommon pathological findings in a rare disease.Archives of medical science : AMS · 2022Article
- Oncologic outcomes of calcitonin-negative medullary thyroid carcinoma.Frontiers in endocrinology · 2022Article
- Calcitonin-negative neuroendocrine tumor of the thyroid with metastasis to liver-rare presentation of an unusual tumor: A case report and review of literature.World journal of clinical cases · 2020Article
- Medullary Thyroid Carcinoma With Elevated Serum CEA and Normal Serum Calcitonin After Surgery: A Case Report and Literature Review.Frontiers in oncology · 2020Article
- Medullary thyroid carcinoma with double negative calcitonin and CEA: a case report and update of literature review.BMC endocrine disorders · 2019Review
- Calcitonin negative Medullary Thyroid Carcinoma: a challenging diagnosis or a medical dilemma?BMC endocrine disorders · 2019Article
- Case report of a neuroendocrine tumor of the thyroid gland with limited calcitonin expression: a diagnostic challenge.AME case reports · 2019Article
- Refractory thyroid carcinoma: which systemic treatment to use?Therapeutic advances in medical oncology · 2018Review
- Plasma Calcitonin Levels and miRNA323 Expression in Medullary Thyroid Carcinoma Patients with or without RET MutationAsian Pacific journal of cancer prevention : APJCP · 2017Article
- Calcitonin-Negative Neuroendocrine Carcinoma of the Thyroid Gland: Case Report and Literature Review.Case reports in oncologyArticle
- CALCITONIN REVISITED IN 2020.Acta endocrinologica (Bucharest, Romania : 2005)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMedullary thyroid carcinoma (MTC) is a relatively uncommon malignant tumor of the parafollicular C cells of the thyroid, which distinguishing feature is the production of calcitonin (CT). CT is a well-recognized tool in the diagnosis and the postsurgical follow-up of patients with MTC with a high sensitivity and specificity, and represents a powerful prognostic indicator. Usually, there is a direct correlation between tumor size and basal CT levels. However, few cases of CT-negative MTCs have been reported in literature and criteria for diagnosis and follow-up are still controversial.
methodsWe performed a brief review on CT-negative MTC and reported our experience on this rare condition, focusing on the clinical characteristics at presentation, the histological and immunostaining features, and the management.
resultsFifteen cases of large, palpable, CT-negative MTCs have been reported in the literature so far; moreover, we reported four cases followed at our center.
conclusionsAlthough CT-negative MTC is rare, normal/low serum levels of CT and CEA cannot completely exclude the possibility of the diagnosis, when suspected. It is well accepted that early diagnosis is crucial, but there is still no consensus on the optimal postoperative surveillance strategy. The ultrasound evaluation of the cervical region, together with abdominal computerized tomography scan, chest X-ray, and fluorine18-fluorodeoxyglucose ((18)F-FDG) PET/computed tomography (FDG-PET/CT), would be recommended in the follow-up of such cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.